German chemical and pharmaceuticals group Bayer AG said Tuesday
the U.S. Food & Drug Administration has granted a priority
review of nexavar for the treatment of differentiated thyroid
cancer.
MAIN FACTS:
-Bayer collaborates with Onyx Pharmaceuticals (ONXX) in the U.S.
on its nexavar drug, also known as sorafenib.
-The FDA grants priority reviews to medicines with the potential
to significantly improve serious conditions.
-The FDA aims to complete the review within six months, rather
than the standard 10 months, Bayer said.
-The decision was based on Phase III trial data showing the drug
significantly extended progression-free survival.
-Thyroid cancer is the sixth most common cancer in women, and
35,000 patients in the world succumb to the disease annually.
-The drug is an oral anti-cancer therapy for liver cancer and
advanced kidney cancer.
-"Nexavar is also being evaluated by Bayer and Onyx,
international study groups, government agencies and individual
investigators in a range of other cancers," Bayer said.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Subscribe to WSJ: http://online.wsj.com?mod=djnwires